Study demonstrates that telehealth appointments increased likelihood that minority patients will return for in-person eye examinations.
An investigation demonstrates continuous and reproducible delivery of ranibizumab after initial and refill-exchange doses.
Researchers reviewed the use of mycophenolate mofetil and methotrexate in cases of noninfectious ocular inflammatory disease.
The study shows the treatment resulted in significantly greater CST reductions and BCVA improvements.
Injections with FAI led to significant improvements in visual acuity, vascular leakage, and OCT thickness at 6 months after treatment.
Three weekly doses of intravitreal AU-011 led to a significant reduction of tumor growth after a year of treatment.
Switch from aflibercept resulted in significant central retinal thickness reductions and visual acuity improvements.
Researchers explored the link between short term ischemic events and presence of retinal microvascular change.
Researchers identify positive prognostic indicators following autologous retinal transplantation.
Earlier treatment with aflibercept improved outcomes in diabetic macular edema.
Researchers examined the incidence and outcome of post-injection endophthalmitis during the COVID-19 pandemic.
Study evaluated the use of single and repeat doses of C1q inhibitor, ANX007, in treating geographic atrophy.
Presenters at the AAO compared faricimab and aflibercept in the treatment of neovascular AMD.
Researchers developed an artificial-intelligence derived vascular severity score to aid in the diagnosis of retinopathy of prematurity.
An AAO 2021 presentation reviewed clinical trial data of intravitreal pegcetacoplan, a targeted C3 inhibitor, in controlling lesion growth in patients with geographic atrophy.
Researchers evaluate the use of the L265P mutation in the MYD88 gene as a diagnostic tool for vitreoretinal lymphoma.
The complications were most commonly seen in patients taking ipilimumab.
Study compares traditional venography with valsalva-assisted CT angiography in identifying drainage to the cavernous sinus.
Study compared brolucizumab (6 mg) to aflibercept (2 mg) in the treatment of diabetic macular edema.
Researchers retrospectively analyzed data of 645,815 patients to determine 1-year transition probabilities.